查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2046895

胃癌治療市場－全球產業規模、佔有率、趨勢、機會與預測：按治療類型、最終用戶、地區和競爭格局分類，2021-2031年

Gastric Cancer Therapy Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapy Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球胃癌治療市場預計將從 2025 年的 41.5 億美元大幅成長至 2031 年的 61.1 億美元，複合年成長率為 6.66%。

該市場涵蓋多種用於治療胃粘膜惡性腫瘤的藥物和生物治療方法，例如化療、標靶治療和免疫調節劑。其成長主要受全球胃癌發病率上升的驅動，而胃癌發病率上升又與人口老化和飲食習慣的改變密切相關，這使得對有效治療方法的需求日益迫切。此外，創新製劑監管核准的不斷增加也促進了市場發展，加速了先進治療方法的引進。然而，開發和使用複雜生物製藥的高昂成本構成了市場發展的一大障礙，限制了患者的用藥，尤其是在醫療成本敏感的地區。嚴格的報銷政策往往會加劇這種經濟障礙，延緩高價值治療方法的推廣。美國癌症協會的統計數據也印證了該疾病的持續影響：預計到2025年，美國將新增30,300例胃癌病例，並有10,780例相關死亡病例。

市場概覽
預測期 2027-2031
市場規模：2025年 41.5億美元
市場規模：2031年 61.1億美元
複合年成長率：2026-2031年 6.66%
成長最快的細分市場 化療
最大的市場 北美洲

市場促進因素

全球胃癌治療市場正經歷重大變革，其主要驅動力是新型免疫療法的日益普及，這些療法正逐漸取代傳統化療，成為晚期胃癌的標準治療方案。免疫查核點抑制劑，尤其是PD-1/PD-L1拮抗劑，已展現出卓越的臨床療效，因此廣泛應用於第一線治療方案。治療方法的轉變顯著提升了市場價值，領先生物製藥的商業性成功便是最好的證明。例如，默克公司於2025年2月宣布，其Keytruda在2024年的總銷售額已達295億美元。這一成長勢頭部分歸功於其在消化器官系統惡性腫瘤適應症方面的擴展。法規核准的里程碑進一步凸顯了推動此應用的臨床療效。 2025年3月，FDA核准Pembrolizumab用於治療HER2陽性胃癌或胃食道交界處腺癌，並指出其聯合治療的總緩解率高達73%，證實了其在改善患者預後方面的有效性。同時，標靶治療治療方法的進展，包括抗體藥物複合體（ADC）以及針對HER2和Claudin 18.2等生物標記的療法，正成為市場成長的關鍵驅動力。這些藥物提供精準的治療方案，在最大限度清除腫瘤的同時，最大限度地降低全身毒性，滿足了精準醫療的迫切需求。這些先進治療方法核准後迅速佔據市場的大部分佔有率，對市場產生了立竿見影的顯著影響。作為這種快速市場滲透的一個例子，BioPharma Dive 在 2025 年 5 月報道稱，靶向抗體藥物複合體Enhertu 在 2024 年的銷售額超過 30 億美元，突顯了精準腫瘤學資產在胃癌領域的盈利潛力。

市場挑戰

研發和使用複雜生物製藥的高昂成本嚴重阻礙了全球胃癌治療市場的擴張。這些先進療法價格昂貴，不僅超出開發中國家醫療系統的負擔能力，也對已開發國家的預算造成了沉重負擔。因此，在疾病負擔往往最重的、對成本高度敏感的地區，患者獲得治療的機會受到嚴重限制，這直接限制了治療量，並減緩了整體市場成長。這種經濟壓力導致支付方採取嚴格的報銷政策，並延遲新治療方法的核准，最終阻礙了這些藥物的市場滲透。癌症治療管理成本的飆升也反映在近期的行業數據中。根據國際員工福利計畫基金會的數據，到2025年，雇主支付的癌症治療費用中位數將年增11%。不斷上漲的成本迫使醫療服務提供者和保險公司優先考慮更便宜的替代方案，而非創新的生物製藥療法，導致胃癌新治療方法的推廣應用停滯不前，並可能降低製藥研發公司的投資回報率。

市場趨勢

雙特異性抗體臨床計畫的拓展正在改變市場格局，使其能夠同時針對不同的腫瘤相關抗原和免疫查核點。這種雙標靶化機制透過提高結合特異性並誘導更強的免疫反應，克服了單特異性抗體的局限性，例如腫瘤異質性和抗藥性。研發人員正積極開發針對HER2/HER2、PD-1/CTLA-4和Claudin 18.2/4-1BB等組合的藥物，以提高晚期胃癌治療的持久性。為了展示這種治療潛力，Jazz Pharmaceuticals於2026年1月宣布，其雙特異性抗體Ziihera在HER2陽性局部進行性或轉移性胃癌（GEA）的一線治療中，使患者的中位總生存期延長了兩年以上，為該患者群體樹立了新的療效標竿。同時，用於非侵入性監測的液態生物檢體技術正作為早期檢測和疾病縱向評估的關鍵手段而廣泛應用。這項技術透過分析循環腫瘤DNA來指導治療方法選擇並早期發現復發，克服了傳統組織切片檢查的局限性。將這些診斷方法納入大規模臨床方案的趨勢凸顯了它們在標準化患者管理方面日益成長的效用。作為檢驗工作的一部分，Guardant Health於2025年7月宣布，已開始招募首批患者參與美國國家癌症研究所（NCI）的先鋒研究（Vanguard Study）。該研究旨在嚴格評估該公司研發的Shield多癌種檢測技術在多達24,000名參與者中識別包括胃癌在內的多種惡性腫瘤的能力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球胃癌治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依治療方法（化療、標靶治療、免疫治療、放射線治療、手術）
    • 按最終使用者（門診手術中心、醫院和專科診所等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美胃癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲胃癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區胃癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲胃癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美胃癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球胃癌治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories Inc.
  • Amgen, Inc.
  • Celltrion Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies Inc.
  • AstraZeneca Plc
  • Pfizer Inc.
  • Eli Lilly & Co.
  • GlaxoSmithKline Plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16096

The Global Gastric Cancer Therapy Market is projected to expand significantly, increasing from USD 4.15 Billion in 2025 to USD 6.11 Billion by 2031, demonstrating a Compound Annual Growth Rate (CAGR) of 6.66%. This market includes a variety of pharmacological and biological treatments for stomach lining malignancies, such as chemotherapy, targeted therapies, and immunomodulators. Its growth is primarily fueled by the increasing global incidence of gastric carcinoma, driven by an aging population and changing dietary habits, which creates a pressing need for effective treatments. Furthermore, the market benefits from a rise in regulatory approvals for innovative drug formulations, accelerating the introduction of advanced therapeutic options.However, the market encounters a considerable hurdle due to the substantial costs associated with the development and administration of complex biologic drugs, which restricts patient access, particularly in regions sensitive to healthcare expenses. This financial barrier is frequently worsened by strict reimbursement policies that delay the adoption of high-value therapies. The persistent impact of this disease is underscored by statistics from the American Cancer Society, which reported an estimated 30,300 new cases of stomach cancer and 10,780 related deaths in the United States in 2025.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.15 Billion
Market Size 2031USD 6.11 Billion
CAGR 2026-20316.66%
Fastest Growing SegmentChemotherapy
Largest MarketNorth America

Market Driver

The Global Gastric Cancer Therapy Market is undergoing a significant transformation, primarily driven by the increasing adoption of novel immunotherapy regimens, which are progressively replacing conventional chemotherapy as the standard of care for advanced-stage gastric cancer. Immune checkpoint inhibitors, especially PD-1/PD-L1 antagonists, have demonstrated superior clinical outcomes, leading to their broad integration into first-line treatment protocols. This therapeutic shift is substantially boosting market value, evidenced by the commercial success of prominent biologic agents. For example, Merck reported in February 2025 that Keytruda generated $29.5 billion in total sales for 2024, a growth trajectory partly attributable to its expanded indications in gastrointestinal malignancies. The clinical efficacy driving this adoption is further highlighted by regulatory milestones, with the FDA's March 2025 approval of pembrolizumab for HER2-positive gastric or gastroesophageal junction adenocarcinoma, noting a confirmed overall response rate of 73% for the combination therapy, validating its potency in improving patient outcomes.Concurrently, the advancement of targeted therapeutic agents, including antibody-drug conjugates (ADCs) and therapies focusing on biomarkers like HER2 and Claudin 18.2, represents a crucial growth engine. These agents provide precise treatment options that minimize systemic toxicity while maximizing tumor eradication, addressing the urgent demand for personalized medicine. The market impact of these sophisticated therapies is both immediate and substantial, as they capture significant revenue share shortly after approval. Illustrating this rapid market penetration, BioPharma Dive reported in May 2025 that the targeted antibody-drug conjugate Enhertu amassed over $3 billion in 2024 revenue, underscoring the lucrative potential of precision oncology assets within the gastric cancer segment.

Market Challenge

The substantial costs associated with the development and administration of complex biologic drugs pose a significant barrier to the expansion of the Global Gastric Cancer Therapy Market. These advanced therapeutics frequently carry premium price tags that surpass the financial capabilities of healthcare systems in developing nations and strain budgets in developed economies. As a result, patient access is severely limited in cost-sensitive regions, where the disease burden is often highest, directly curtailing the volume of therapies administered and dampening overall market revenue growth.This financial pressure leads payers to enforce stringent reimbursement policies and delay coverage approvals for novel treatments, thereby impeding the commercial uptake of these drugs. The escalating expense of oncology management is evident in recent industry data; according to the International Foundation of Employee Benefit Plans, the median spend on cancer care by employers increased by 11 percent in 2025 compared to the previous year. Such rising costs compel healthcare providers and insurers to prioritize less expensive alternatives over innovative biologic interventions, consequently stalling the widespread adoption of new gastric cancer therapies and reducing the potential return on investment for pharmaceutical developers.

Market Trends

The proliferation of bispecific antibody clinical programs is significantly transforming the market by enabling the simultaneous targeting of distinct tumor-associated antigens or immune checkpoints. This dual-targeting mechanism addresses the limitations of monospecific antibodies, such as tumor heterogeneity and drug resistance, by enhancing binding specificity and triggering more potent immune responses. Developers are actively advancing assets that target combinations like HER2/HER2, PD-1/CTLA-4, and Claudin 18.2/4-1BB to improve treatment durability in advanced gastric cancer. Validating this therapeutic potential, Jazz Pharmaceuticals announced in January 2026 that the bispecific antibody Ziihera demonstrated a median overall survival benefit exceeding two years in first-line HER2+ locally advanced or metastatic GEA, establishing a new benchmark for efficacy in this patient population.Concurrently, the integration of liquid biopsy for non-invasive monitoring is expanding as a crucial method for early detection and longitudinal disease assessment. This technology addresses the challenges associated with traditional tissue biopsies by analyzing circulating tumor DNA to guide treatment selection and detect recurrence earlier. The shift towards incorporating these diagnostics into large-scale clinical protocols highlights their increasing utility in standardizing patient management. Illustrating this commitment to validation, Guardant Health announced in July 2025 the enrollment of the first patient in the National Cancer Institute's Vanguard Study, which aims to rigorously evaluate the performance of its Shield Multi-Cancer Detection Test in identifying various malignancies, including gastric cancer, by enrolling up to 24,000 participants.

Key Market Players

  • Abbott Laboratories Inc.
  • Amgen, Inc.
  • Celltrion Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies Inc.
  • AstraZeneca Plc
  • Pfizer Inc.
  • Eli Lilly & Co.
  • GlaxoSmithKline Plc

Report Scope

In this report, the Global Gastric Cancer Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gastric Cancer Therapy Market, By Therapy Type

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Radiation Therapy
  • Surgery

Gastric Cancer Therapy Market, By End User

  • Ambulatory Surgery Centers
  • Hospitals and Specialty Clinics
  • Other

Gastric Cancer Therapy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gastric Cancer Therapy Market.

Available Customizations:

Global Gastric Cancer Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gastric Cancer Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery)
    • 5.2.2. By End User (Ambulatory Surgery Centers, Hospitals and Specialty Clinics, Other)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Gastric Cancer Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Gastric Cancer Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Gastric Cancer Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Gastric Cancer Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy Type
        • 6.3.3.2.2. By End User

7. Europe Gastric Cancer Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Gastric Cancer Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Gastric Cancer Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Gastric Cancer Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Gastric Cancer Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Gastric Cancer Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Gastric Cancer Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Gastric Cancer Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Gastric Cancer Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Gastric Cancer Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Gastric Cancer Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Gastric Cancer Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Gastric Cancer Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Gastric Cancer Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Gastric Cancer Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Gastric Cancer Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy Type
        • 9.3.3.2.2. By End User

10. South America Gastric Cancer Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Gastric Cancer Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Gastric Cancer Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Gastric Cancer Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Gastric Cancer Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amgen, Inc.
  • 15.3. Celltrion Inc.
  • 15.4. Novartis AG
  • 15.5. F. Hoffmann-La Roche Ltd
  • 15.6. Agilent Technologies Inc.
  • 15.7. AstraZeneca Plc
  • 15.8. Pfizer Inc.
  • 15.9. Eli Lilly & Co.
  • 15.10. GlaxoSmithKline Plc

16. Strategic Recommendations

17. About Us & Disclaimer